Our Products
Loans
Cards
Insurance
Investment
Stock Market
Electronics Mall
CIBIL Score
Knowledge Centre
Academy 
Calculators
Our Services
Cibil Report
Get cibil report
My Account
Log In
Log into your account
Offers
Check out pre-approved offers now!
Languages
Chosen Language: English
Do Not Call
Do not call
En
Panacea Biotec Ltd. Share Price
N/A
1D
1M
3M
6M
1Y
5Y
Day's Range
Day's Range
Low
₹420.00
High
₹439.20
Price Summary
| Previous Close | ₹422.55 |
|---|---|
| Day's Range | ₹420.00 - ₹439.20 |
| Open | ₹420.00 |
| 52 Week Range | ₹292.40 - ₹549.70 |
| Volume | 1,29,194 |
| Market Cap | ₹0.00 |
| Previous Close | ₹421.25 |
|---|---|
| Day's Range | ₹418.60 - ₹438.90 |
| Open | ₹418.60 |
| 52 Week Range | ₹293.10 - ₹555.15 |
| Volume | 9,824 |
| Market Cap | ₹0.00 |
Stocks Summary
| Trade Value ( ₹ in Lacs) | 545.91 |
|---|---|
| Market Cap (₹ in Mn) | 0.00 |
| Dividend Yield(%) | 0.00 |
| Price/Earning (TTM) | 0.00 |
| TTM EPS (₹) | -1.27 |
| P/E Ratio | 0.00 |
| Book Value(₹) | 3.09 |
| PAT Margin (%) | -1.55 |
| Face Value (₹) | 1.00 |
| ROCE(%) | -0.47 |
| Trade Value ( ₹ in Lacs) | 41.38 |
|---|---|
| Market Cap (₹ in Mn) | 0.00 |
| Dividend Yield(%) | 0.00 |
| Price/Earning (TTM) | 0.00 |
| TTM EPS (₹) | -1.27 |
| P/E Ratio | 0.00 |
| Book Value(₹) | 3.09 |
| PAT Margin (%) | -1.55 |
| Face Value (₹) | 1.00 |
| ROCE(%) | -0.47 |
Financials
| Particulars | QTR FY (₹ in Millions) | Annual FY (₹ in Millions) |
|---|---|---|
| Net sales | 1084.3 | 3596.0 |
| Expenses | N/A | N/A |
| PBT | 96.5 | 42.1 |
| Operating profit | 0.0 | 0.0 |
| Net profit | 96.5 | 35.5 |
About Panacea Biotec Ltd.
| Founded | 1984 |
|---|---|
| Managing Director | Rajesh Jain |
| NSE Symbol | PANACEABIO |
Peer Comparision
| Stocks Name | Market Cap (Cr)(₹) | Market Price (₹) | 52 Week Low-High (₹) |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | 4,41,789.55 | 1,832.05 | 1,548.00 - 1,548.00 |
| Divi's Laboratories Ltd. | 1,79,450.12 | 6,709.95 | 5,636.50 - 5,636.50 |
| Torrent Pharmaceuticals Ltd. | 1,54,733.87 | 4,423.00 | 3,102.00 - 3,102.00 |
| Apollo Hospitals Enterprise Ltd. | 1,20,848.85 | 8,254.90 | 6,696.50 - 6,696.50 |
| Cipla Ltd. | 1,14,182.61 | 1,417.35 | 1,165.70 - 1,165.70 |
| Dr. Reddy's Laboratories Ltd. | 1,11,184.65 | 1,330.00 | 1,148.40 - 1,148.40 |
| Zydus Lifesciences Ltd. | 1,07,973.94 | 1,079.50 | 835.50 - 835.50 |
| Lupin Ltd. | 1,04,613.28 | 2,259.40 | 1,836.80 - 1,836.80 |
| Mankind Pharma Ltd. | 1,01,443.53 | 2,419.00 | 1,909.70 - 1,909.70 |
| Max Healthcare Institute Ltd. | 97,382.77 | 991.30 | 903.00 - 903.00 |
No Records Found
Latest News
May
7
2026
Posted on May 7th 2026
Panacea Biotec informs about updates
Panacea Biotec has informed that it enclosed details of shares dematerialised during April 2026 under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018.
The above information is a part of company’s filings submitted to BSE.
Read More
Apr
30
2026
Posted on Apr 30th 2026
Panacea Biotec informs about disclosure
Pursuant to Regulation 30 read with Para B of Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (SEBI LODR Regulations), Panacea Biotec has informed that the Income Tax Appellate Tribunal (ITAT) vide its Order dated April 29, 2026, allowed the appeal filed by the Company and set aside the Order dated August 14, 2025 of Commissioner of Income Tax (Appeals) (CIT(A)) arising out of Rectified Assessment Order dated October 10, 2023 passed earlier by Assessing Officer u/s 143(3) read with section 154 of the Income Tax Act, 1961 (Act). As per the aforesaid Rectified Assessment Order dated October 10, 2023, the Assessing Officer raised a demand of ₹9.16 Crore for Assessment Year 2020-21 on account of addition of ₹3.44 Crore under Section 14A of the Act read with Rule 8D of the Income Tax Rules, 1962. The aforesaid ITAT Order effectively results in deletion of the said disallowances of expenses as well as cancellation of demand of ₹9.16 Crore previously raised by Assessing Officer for the Assessment Year 2020- 21. The requisite details as required under Regulation 30 of the SEBI LODR Regulations read with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, and Industry Standards on Regulation 30 of SEBI LODR Regulations, are annexed as Annexure A.
The above information is a part of company’s filings submitted to BSE.
Read More
Apr
1
2026
Posted on Apr 1st 2026
Panacea Biotec informs about completion of tenure of independent director
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (‘SEBI LODR Regulations’), Panacea Biotec has informed that Mukul Gupta (DIN: 00254597), Independent Director of the Company has completed his second and final term of 5 consecutive years as Independent Director on March 31, 2026 and accordingly he has ceased to be an Independent director of the Company. Consequently, he has also ceased to be the Chairperson / member of the Committees of the Board of Directors of the Company. The Board of Directors and the Management of the Company express deep appreciation and gratitude to Mukul Gupta for his extensive contribution and guidance towards the business growth of the Company. The details required to be disclosed under Regulation 30 of the SEBI LODR Regulations read with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, are enclosed as Annexure - A.
The above information is a part of company’s filings submitted to BSE.
Read More
May
26
2026
Posted on May 26th 2026
Sudarshan Pharma Industries informs about newspaper advertisement
Sudarshan Pharma Industries has informed that it enclosed the newspaper advertisement for the Postal Ballo Notice dispatched to the shareholders of the Company on 25/May/2026 published in (i) Mumbai Lakshdeep and (ii) Financial Express.
The above information is a part of company’s filings submitted to BSE.
Read More
May
26
2026
Posted on May 26th 2026
Fredun Pharma - Quaterly Results
A decent increase of about 27.27% in the sales to Rs. 2130.52 millions was observed for the quarter ended March 2026. The sales figure stood at Rs. 1674.08 millions during the year-ago period.Net profit for the quarter ended March 2026 increased significantly by 56.45% to Rs. 110.64 millions from Rs. 70.72 millions.OP of the company witnessed a marginal growth to 291.30 millions from 174.39 millions in the same quarter last year.
| (Rs. in Million) |
| Quarter ended | Year to Date | Year ended | |||||||
| 202603 | 202503 | % Var | 202603 | 202503 | % Var | 202603 | 202503 | % Var | |
| Sales | 2130.52 | 1674.08 | 27.27 | 6391.21 | 4562.68 | 40.08 | 6391.21 | 4562.68 | 40.08 |
| Other Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| PBIDT | 291.30 | 174.39 | 67.04 | 947.94 | 550.97 | 72.05 | 947.94 | 550.97 | 72.05 |
| Interest | 144.85 | 81.47 | 77.80 | 392.98 | 223.77 | 75.62 | 392.98 | 223.77 | 75.62 |
| PBDT | 146.45 | 92.92 | 57.61 | 554.96 | 327.20 | 69.61 | 554.96 | 327.20 | 69.61 |
| Depreciation | 31.13 | 12.50 | 149.04 | 79.14 | 44.49 | 77.88 | 79.14 | 44.49 | 77.88 |
| PBT | 115.32 | 80.42 | 43.40 | 475.82 | 282.71 | 68.31 | 475.82 | 282.71 | 68.31 |
| TAX | 4.68 | 9.70 | -51.75 | 143.75 | 74.63 | 92.62 | 143.75 | 74.63 | 92.62 |
| Deferred Tax | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| PAT | 110.64 | 70.72 | 56.45 | 332.07 | 208.08 | 59.59 | 332.07 | 208.08 | 59.59 |
| Equity | 54.73 | 47.22 | 15.90 | 54.73 | 47.22 | 15.90 | 54.73 | 47.22 | 15.90 |
| PBIDTM(%) | 13.67 | 10.42 | 31.25 | 14.83 | 12.08 | 22.83 | 14.83 | 12.08 | 22.83 |
Read More
No Records Found
Sign in to Unlock Offers!
We don't SPAM
Frequently Asked Questions
The current share price of Panacea Biotec Ltd. is ₹422.55 as of 2026-05-26.
The market capitalisation of Panacea Biotec Ltd. is ₹2,563.96 as of 2026-05-25.
The 1-year return of Panacea Biotec Ltd. is 3.50% as of 2026-05-26.
The P/E ratio of Panacea Biotec Ltd. is 0.00 as of 2026-05-26.
The 52-week high and low of Panacea Biotec Ltd. are ₹549.70 and ₹292.40, respectively, as of 2026-05-26.
View More
Disclaimer
All content and research information displayed on the Site, are obtained from our partner Accord Fintech Private Limited. an authorized data feed vendor of BSE/NSE/MCX/NCDEX exchange. The data is provided on ‘As-Is’ basis and is not a live data feed but a feed with 15 minutes delay or more. Bajaj Markets does not warrant accuracy, completeness, timely availability of the information and data available on the Site. Past performance, when presented, is purely for reference purposes and is not a guarantee of similar future results.
The Services offered on the Site does not constitute investment advice in any manner whatsoever. You shall be solely responsible for any investment decisions made by placing reliance on the information provided on the Site.
Bajaj Markets partners with financial services entities for sourcing leads for services such as DEMAT accounts etc. In case you wish to avail the services, you shall be redirected to partners platform and shall be bound by the terms and conditions, privacy policy governing the said platform.
Home
Shopping
Loan Offers
My Accounts
Explore
